Materion Reports Q4 2025 Results, Beats Estimates and Projects Strong 2026 Outlook

MTRN
February 12, 2026

Materion Corporation (NYSE: MTRN) announced today its fourth‑quarter and full‑year 2025 financial results, reporting net sales of $489.7 million for the quarter and $1.79 billion for the year, up 10.5% and 6.4% respectively from the prior year. The company posted adjusted EBITDA of $57.0 million in Q4, representing 22.5% of value‑added sales, and adjusted net income of $32.0 million, or $1.53 per diluted share, compared with a loss of $2.33 per share in the same period a year earlier. Materion’s CEO, Jugal Vijayvargiya, highlighted strong performance in its Electronic Materials and Precision Optics segments, driven by semiconductor, energy, and data‑center demand, and noted that the company’s cost‑structure improvements are supporting margin expansion.

In its outlook, Materion guided to a 2026 adjusted earnings‑per‑share range of $6.00 to $6.50, a 15% increase from the 2025 midpoint of $5.30 to $5.70. The company reiterated its commitment to achieving a mid‑term adjusted EBITDA margin target of 23% and emphasized continued growth in defense and semiconductor markets. Materion also announced a $65 million customer investment to support U.S. defense initiatives, underscoring its strategic focus on high‑value defense contracts.

The earnings release confirms that Materion’s transformation strategy—portfolio pruning, facility rightsizing, and a pivot to higher‑margin semiconductor and defense applications—is delivering tangible results. The company’s ability to beat earnings estimates, maintain robust top‑line growth, and raise guidance signals confidence in its execution and positions Materion favorably for the upcoming defense spending cycle and semiconductor recovery.

The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.